1-Isopropyl-4-(2-pyridylmethyl)piperazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-Isopropyl-4-(2-pyridylmethyl)piperazine
• 英文别名: 1-propan-2-yl-4-(pyridin-2-ylmethyl)piperazine
• 化学式: C₁₃H₂₁N₃
• 分子量: 219.33
• InChiKey: LLHCLZMIMOEPFZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  19.4
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• FAST-DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS
  申请人：MacDonald Gregor James

  公开号：US20100069394A1

  公开（公告）日：2010-03-18

  The present invention relates to 4-aryl-6-piperazin-1-yl-3-substituted-pyridazines that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds find utility as medicines for treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect without motor side effects.

  本发明涉及4-芳基-6-哌嗪-1-基-3-取代吡啶嗪，它们是快速解离的多巴胺2受体拮抗剂，制备这些化合物的方法，以及包含这些化合物作为活性成分的制药组合物。这些化合物可用作治疗或预防中枢神经系统疾病的药物，例如精神分裂症，通过发挥抗精神病作用而不产生运动副作用。
• IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS
  申请人：Marmsater Fredrik P.

  公开号：US20100144751A1

  公开（公告）日：2010-06-10

  Compounds of Formula (I): are receptor tyrosine inhibitors useful in the treatment of diseases mediated by class (3) and class (5) receptor tyrosine kinases. Particular compounds of this invention have also been found to be inhibitors of Pim-1.

  化学式（I）的化合物是受体酪氨酸激酶抑制剂，可用于治疗由类（3）和类（5）受体酪氨酸激酶介导的疾病。该发明的特定化合物也被发现是Pim-1的抑制剂。
• Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
  申请人：Array BioPharma, Inc.

  公开号：US10023570B2

  公开（公告）日：2018-07-17

  Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

  本文提供的是通式 I 的化合物： 及其立体异构体和药学上可接受的盐或溶液，其中 A、B、D、E、X1、X2、X3 和 X4 具有说明书中给出的含义，它们是 RET 激酶的抑制剂，可用于治疗和预防可以用 RET 激酶抑制剂治疗的疾病，包括由 RET 激酶介导的疾病或紊乱。
• Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
  申请人：Array BioPharma, Inc.

  公开号：US10174027B2

  公开（公告）日：2019-01-08

  Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

  本文提供的是通式 I 的化合物： 及其立体异构体和药学上可接受的盐或溶液，其中 A、B、D、E、X1、X2、X3 和 X4 具有说明书中给出的含义，它们是 RET 激酶的抑制剂，可用于治疗和预防可以用 RET 激酶抑制剂治疗的疾病，包括由 RET 激酶介导的疾病或紊乱。
• Tricyclic gyrase inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10858360B2

  公开（公告）日：2020-12-08

  Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.

  本文公开了具有式 I 结构的化合物及其药学上适用的盐、酯和原药，它们可作为抗菌有效的三环回旋酶抑制剂。 还考虑了相关的药物组合物、用途和化合物的制造方法。